Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors

Table 2

Subgroup comparisons of SSTR2A, IGF-1R, and p-mTOR QSs.

		SSTR2A QS		IGF-1R QS		p-mTOR QS
		Median (IQR)		Median (IQR)		Median (IQR)
Gender	F	4.6 (1.0–6.4)	0.593	0.3 (0.0–3.2)	0.496	3.0 (0.8–4.9)	0.180
	M	2.7 (1.1–7.2)		0.3 (0.0–1.8)		3.6 (1.1–8.5)
Syndrome	Yes	2.4 (0.0–6.0)	0.116	0.5 (0.0–3.2)	0.707	1.0 (0.0–4.9)	0.033
	No	4.3 (1.3–7.2)		0.3 (0.0–2.3)		3.5 (1.9–6.7)
Primary	Pancreas	4.8 (1.0–6.5)	0.801	0.5 (0.0–2.9)	0.276	2.0 (0.8–3.4)	<0.001
	GI	3.0 (1.1–6.4)		0.2 (0.0–1.8)		6.7 (3.1–8.8)
Stage	I-II	6.4 (3.0–8.0)	<0.001	1.1 (0.1–3.3)	0.002	2.0 (0.3–3.6)	<0.001
	IIIB-IV	2.1 (0.6–4.2)		0.0 (0.0–0.7)		5.0 (2.7–8.5)
Grading	G1	4.3 (1.0–7.6)	0.158	0.9 (0.0–3.2)	0.005	2.9 (0.6–5.6)	0.143
	G2	2.8 (0.8–5.6)		0.0 (0.0–0.4)		4.0 (2.0–6.1)

SSTR2A: somatostatin receptor 2A; IGF-1R: insulin-like growth factor-1 receptor; p-mTOR: phosphorylated mammalian target of rapamycin; QS: quantitative score; IQR: interquartile range; GI: gastrointestinal.